Avidity Biosciences Inc
RNA37.200USD
+1.280+3.56%
交易中 （美东）报价延迟15分钟
4.48B总市值
亏损市盈率 TTM
关于 Avidity Biosciences Inc 公司
Avidity Biosciences, Inc. 是一家生物制药公司。该公司致力于提供一种称为抗体寡核苷酸偶联物 (AOC) 的新型核糖核酸 (RNA) 疗法。AOC 旨在将单克隆抗体的特异性与寡核苷酸疗法的精确性相结合，以解决现有 RNA 疗法以前无法触及的目标和疾病。其不断推进和扩展的管道有三个临床开发项目。AOC 1001 旨在治疗患有 1 型肌强直性营养不良症 (DM1) 的人，并且与正在进行的 MARINA 开放标签扩展研究 (MARINA-OLE) 一起处于 I/II 期开发阶段。AOC 1044 专为杜氏肌营养不良症患者设计，并且与 EXPLORE44 试验一起处于 I/II 期开发阶段。 AOC 1020 旨在治疗面肩肱型肌营养不良症 (FSHD) 患者，目前正与 FORTITUDE 试验一起处于 I/II 期开发阶段。
公司简介
公司代码RNA
公司名称Avidity Biosciences Inc
上市日期Jun 12, 2020
CEOMs. Sarah Boyce
员工数量391
证券类型Ordinary Share
年结日Jun 12
公司地址10578 Science Center Drive
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编92121
电话18584017900
网址https://www.aviditybiosciences.com/
公司代码RNA
上市日期Jun 12, 2020
CEOMs. Sarah Boyce
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
+105.68%
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
+0.99%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
50.00K
+100.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.64K
-1.80%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
6.69K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
6.69K
--
Dr. W. Michael Flanagan, Ph.D.
Dr. W. Michael Flanagan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Eric B. Mosbrooker
Mr. Eric B. Mosbrooker
Chief Commercial Officer
Chief Commercial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
+105.68%
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
+0.99%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
50.00K
+100.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.64K
-1.80%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
收入明细
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
暂无数据
地区USD
名称
营收
占比
United States
1.57M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
12.69%
Janus Henderson Investors
9.48%
T. Rowe Price Associates, Inc.
9.30%
Wellington Management Company, LLP
8.03%
The Vanguard Group, Inc.
7.65%
Other
52.85%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
12.69%
Janus Henderson Investors
9.48%
T. Rowe Price Associates, Inc.
9.30%
Wellington Management Company, LLP
8.03%
The Vanguard Group, Inc.
7.65%
Other
52.85%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
47.08%
Investment Advisor
46.95%
Hedge Fund
6.31%
Venture Capital
5.98%
Corporation
4.21%
Research Firm
2.59%
Private Equity
1.94%
Individual Investor
1.01%
Sovereign Wealth Fund
0.60%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
495
141.64M
117.51%
-2.91M
2025Q1
508
142.16M
117.97%
-7.67M
2024Q4
492
135.01M
112.33%
-12.86M
2024Q3
467
132.62M
112.76%
+3.34M
2024Q2
414
118.94M
111.18%
+14.23M
2024Q1
365
96.48M
102.78%
+1.47M
2023Q4
345
83.09M
112.13%
-13.56M
2023Q3
334
86.17M
118.19%
-15.24M
2023Q2
328
86.81M
124.27%
-3.56M
2023Q1
328
80.46M
115.95%
-5.12M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
15.29M
12.69%
-866.01K
-5.36%
Mar 31, 2025
Janus Henderson Investors
11.43M
9.48%
+4.37M
+62.01%
Mar 31, 2025
T. Rowe Price Associates, Inc.
11.21M
9.3%
+289.32K
+2.65%
Mar 31, 2025
Wellington Management Company, LLP
9.68M
8.03%
+1.58M
+19.47%
Mar 31, 2025
The Vanguard Group, Inc.
9.22M
7.65%
-188.71K
-2.01%
Mar 31, 2025
RTW Investments L.P.
8.75M
7.26%
+814.06K
+10.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.40M
6.96%
-22.20K
-0.26%
Mar 31, 2025
Avoro Capital Advisors LLC
7.63M
6.33%
+125.00K
+1.67%
Mar 31, 2025
RA Capital Management, LP
6.30M
5.23%
--
--
Mar 31, 2025
Bristol Myers Squibb
5.08M
4.21%
--
--
Sep 30, 2024
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Global X Genomics & Biotechnology ETF
3.64%
ALPS Medical Breakthroughs ETF
2.32%
Tema Neuroscience and Mental Health ETF
1.72%
SPDR S&P Biotech ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
0.5%
ProShares Ultra Nasdaq Biotechnology
0.38%
Invesco Nasdaq Biotechnology ETF
0.38%
iShares Biotechnology ETF
0.32%
查看更多
Global X Genomics & Biotechnology ETF
占比3.64%
ALPS Medical Breakthroughs ETF
占比2.32%
Tema Neuroscience and Mental Health ETF
占比1.72%
SPDR S&P Biotech ETF
占比0.91%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.8%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.5%
ProShares Ultra Nasdaq Biotechnology
占比0.38%
Invesco Nasdaq Biotechnology ETF
占比0.38%
iShares Biotechnology ETF
占比0.32%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
